Key Inclusion Criteria:

          -  Provide written, informed consent to participate in the study and follow the study
             procedures

          -  Karnofsky Performance Status (KPS) of at least 70%

          -  Measurable disease per mRECIST 1.1 criteria

          -  Histologically confirmed RCC with a clear-cell component (may have sarcomatoid
             features); advanced (not amenable to curative surgery or radiation therapy) or
             metastatic (AJCC Stage IV) RCC

          -  Patients with any International Metastatic Renal Cell Carcinoma Database Consortium
             (IMDC) score (favorable-, intermediate-, or poor-risk) are eligible. At least one IMDC
             prognostic factor must be present to qualify as either intermediate- or poor-risk
             renal cell carcinoma.

          -  No prior systemic therapy (including neoadjuvant, adjuvant, or vaccine therapy) for
             RCC

          -  Patients with stable brain metastases following local treatment may be enrolled if
             certain criteria are met

          -  Tumor tissue (archival or fresh biopsy) identified and available for PD-L1 testing

          -  Adequate organ function without growth factor or transfusion support

        Key Exclusion Criteria:

          -  An active, known or suspected autoimmune disease that has required systemic treatment
             within the past 3 months (exceptions exist)

          -  Patients who have a known additional malignancy that is progressing or requires active
             treatment (exceptions exist)

          -  Any tumor invading the wall of a major blood vessels

          -  Any tumor invading the gastrointestinal (GI) tract or any evidence of endotracheal or
             endobronchial tumor within 28 days prior to randomization

          -  Need for >2 medications for management of hypertension (including diuretics)

          -  History of pulmonary embolism, deep vein thrombosis (not including tumor thrombus), or
             clinically significant thromboembolic event within 3 months of randomization

        Additional protocol defined inclusion/exclusion criteria and exceptions apply